A virologic response as a hallmark of excellence: TDF/FTC or TDF/3TC
- Authors: Kozyrina N.V1, Yurin O.G1
-
Affiliations:
- Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
- Issue: No 6 (2015)
- Pages: 27-29
- Section: Articles
- URL: https://journals.eco-vector.com/2226-6976/article/view/278356
- ID: 278356
Cite item
Open Access
Access granted
Abstract
In accordance with most guidelines, tenofovir disoproxil fumarate (TDF) that is usually combined with emtricitabine (FTC) is a constituent of the nucleoside basis for an antiretroviral therapy regimen. This combination is used as part of first-line antiretroviral therapy. TDF may be concurrently administered with lamivudine (3TC). The review describes the data of comparable retrospective studies of the virologic efficiency of TDF/FTC and TDF/3TC regimens. The given works show a better virologic response when using the TDF/FTC regimen. And along with this, there are investigations that have shown no difference in a virologic response when using these nucleoside bases in the therapy regimens. It is concluded that the virologic efficacy of the TDF/FTC combination cannot be at least extrapolated to other TDF combinations in clinical practice.
Full Text
About the authors
N. V Kozyrina
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: nad-kozyrina@yandex.ru
O. G Yurin
Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Welfare
Email: oleg_gerald@mail.ru
References
- Ускорение: прекращение эпидемии СПИДа к 2030 году. ЮНЭЙДС, 2014. http://www.unaids.org/sites/default/ files/media_asset/JC2686_WAD2014report_ru.pdf
- Проект Перечня ЖНВЛС на 2016 г. http://www. rosminzdrav.ru/ministry/61/10/stranitsa-858/rezultaty-zasedaniy-komissii-minzdrava-rossii-po-formirovaniyu-perechney-lekarstvennyh-preparatov
- Инструкция по медицинскому применению препарата кивекса. http://arvt.ru/sites/default/files/Kivexa.pdf
- Инструкция по медицинскому применению препарата трувада. http://arvt.ru/drugs/combined-ARV/Truvada. html
- Rokx C., Fibriani A., Vijver D., Verbon A., Schutten M., Gras L., Rijnders B.J.; AIDS Therapy Evaluation in the Netherlands National Observational Cohort. Increased virological failure in naive HIV-1-infected patients taking lamivudine compared with emtricitabine in combination with tenofovir and efavirenz or nevirapine in the Dutch Nationwide ATHENA Cohort. Clin. Infec. Dis. 2015; 60(1): 143-153. PubMed PMID: 25273080.
- Mulenga L., Muwango A., Moyo C., Mweemba A., Musonda P., Mulenga P. Efficacy of tenofovir disoproxil fumarate/emtricitabine and tenofovir disoproxil both in combination with efavirenz in antiretroviral-naïve, HIV-1-infected Zambians. Program and abstracts of the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Kuala Lumpur, Malaysia, 2013; TULBPE18.
- Swartz1 J. E., Vandekerckhove L., Ammerlaan H., A. de Vries C., Begovac J., Bierman W. F. W., Boucher C.A., van der Ende M.E., Grossman Z., Kaiser R., Levy I., Mudrikova T., Paredes R., Perez-Bercoff D., Pronk M., Richter C., Schmit J.C., Vercauteren J., Zazzi M., Zidovec Lepej S., De Luca A., Wensing A.M; on behalf of the European Society for translational Antiviral Research (ESAR). Efficacy of tenofovir and efavirenz in combination with lamivudine or emtricitabine in antiretroviral-naive patients in Europe. J. Antimicrob. Chemother. 2015; 70(6): 1850-1857.
Supplementary files
